Ally Bridge Group’s Cerevel Therapeutics Holdings CERE Stock Holding History
Bought
Maintained
Sold
Other funds holding CERE
Ally Bridge Group's CERE Position: Q3 2022 in Review
Ally Bridge Group sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2022, closing a stake of 170,000 shares — an estimated $4.5M sold.
Ally Bridge Group first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $29.3M in Q4 2020. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.
- Ally Bridge Group reported no remaining Cerevel Therapeutics Holdings position as of Q3 2022 after selling out during the quarter.
- Ally Bridge Group sold 170,000 Cerevel Therapeutics Holdings shares in Q3 2022, an estimated $4.5M.
- Ally Bridge Group first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 5 quarters.
- Ally Bridge Group's Cerevel Therapeutics Holdings position peaked at $29.3M in Q4 2020.
- 114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2022.
Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.